Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A Plus Biotechnology CoTPE:6918 +0.54%72 EV-to-FCF is 69.48 as of Aug. 22, 2026, which is 243% above its 10-year median of 20.24. GuruFocus rates TPE:6918 with a GF Score™ of 72/100 and a GF Value™ of NT$86.60 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 404 Medical Devices & Instruments companies, A Plus Biotechnology Co ranks worse than 83.17% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, A Plus Biotechnology Co's Enterprise Value is NT$2,225.1 Mil.
A Plus Biotechnology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was NT$32.0 Mil. Therefore, A Plus Biotechnology Co's EV-to-FCF for today is 69.48.
The historical rank and industry rank for A Plus Biotechnology Co's EV-to-FCF or its related term are showing as below:
TPE:6918'
s EV-to-FCF Range Over the Past 10 Years
Min: 13.67 Med: 20.24 Max: 104.23
Current: 69.48
During the past 7 years, the highest EV-to-FCF of A Plus Biotechnology Co was 104.23. The lowest was 13.67. And the median was 20.24.
TPE:6918's EV-to-FCF is ranked worse than 83.17% of 404
companies
in the Medical Devices & Instruments industry
Industry Median: 23.565
vs TPE:6918: 69.48
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
A Plus Biotechnology Co (TPE:6918) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
A Plus Biotechnology Co's PE Ratio (TTM) for today is calculated as:
A Plus Biotechnology Co's share price for today is NT$74.40.
A Plus Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$5.390.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, A Plus Biotechnology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
A Plus Biotechnology Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, A Plus Biotechnology Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where A Plus Biotechnology Co's EV-to-FCF falls into.
A Plus Biotechnology Co's current Enterprise Value is NT$2,225.1 Mil.
A Plus Biotechnology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$32.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A Plus Biotechnology Co (TPE:6918) has a EV-to-FCF of 69.48 as of Aug. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on A Plus Biotechnology Co and its competitors. This is 243% above median its historical median of 20.24. Over the past decade, A Plus Biotechnology Co's EV-to-FCF has ranged from 13.67 to 104.23. According to the industry distribution chart, A Plus Biotechnology Co ranks #336 out of 404 companies in the Medical Devices & Instruments industry, placing it in the top 83.2%.
Is A Plus Biotechnology Co's EV-to-FCF too high?
A Plus Biotechnology Co's current EV-to-FCF of 69.48 is 243% above median its 10-year median of 20.24. Over the past 10 years, this metric has ranged from a low of 13.67 to a high of 104.23. The Medical Devices & Instruments industry median EV-to-FCF is 23.57. A Plus Biotechnology Co's value of 69.48 is 194.8% above this industry median. Based on the distribution chart, A Plus Biotechnology Co ranks #336 out of 404 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, A Plus Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, A Plus Biotechnology Co ranks #336 out of 404 companies for EV-to-FCF. This places A Plus Biotechnology Co in the lower half of its industry. The industry median EV-to-FCF is 23.57. A Plus Biotechnology Co's value of 69.48 is 194.8% above this benchmark. Historically, A Plus Biotechnology Co's own EV-to-FCF has ranged from 13.67 to 104.23 over the past decade. While the company's 10-year median is 20.24 vs. the industry median of 23.57, A Plus Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.57, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. A Plus Biotechnology Co's current EV-to-FCF of 69.48 is 194.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on A Plus Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. A Plus Biotechnology Co's current EV-to-FCF is 69.48, which is 243% above median its own 10-year median of 20.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$86.60, compared to a current price of NT$74.40 — trading 14.1% below its estimated fair value. The current EV-to-FCF is 69.48, which is 243% above median its 10-year median of 20.24 and 194.8% above the Medical Devices & Instruments industry median of 23.57. A Plus Biotechnology Co's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current EV-to-FCF is 69.48 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?
Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued.
The current stock price of NT$74.40 is trading 14.1% below its estimated GF Value™ of NT$86.60.
GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.
Key valuation signals for TPE:6918:
EV-to-FCF: 69.48 (243% above median its 10-year median of 20.24)
GF Value™: NT$86.60 vs. price of NT$74.40 (14.1% below fair value)
Industry Position: 194.8% above the Medical Devices & Instruments median (#336 of 404)
No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
72GF Score
Get the complete analysis for TPE:6918
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6918 has been successfully added to your 
